Transforming growth factor β and the liver

Hepatology

Volumn 34, Issue 5, 2001, Pages 859-867

  Bissell, D Montgomery ^a   Roulot, Dominique ^a,b   George, Jacob ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; BONE MORPHOGENETIC PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

APOPTOSIS; CELL MIGRATION; CELL PROLIFERATION; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; LIVER DEVELOPMENT; LIVER FIBROSIS; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0034767501     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.28457     Document Type: Article

References (137)

1. Controlling TGF-beta signaling
2. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes
3. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease
4. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction
5. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation
6. All-trans-retinoic acid increases transforming growth factor-beta2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor-alpha-dependent signaling pathway
7. Diminished retinoic acid signaling in hepatic stellate cells in cholestatic liver fibrosis
8. Retinoic acid modulates rat Ito cell proliferation, collagen, and transforming growth factor beta production
9. Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF-beta in liver stellate cells
10. Transcriptional activation of transforming growth factor betal and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Spl. Potential mechanisms for autocrine fibrogenesis in response to injury
11. Mechanical stretch modulates TGF-beta1 and alpha1
12. Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins
13. Recombinant latent transforming growth factor-binding protein 2 assembles to fibroblast extracellular matrix and is susceptible to proteolytic processing and release
14. Expression and release of the latent transforming growth factor beta binding protein by hepatocytes from rat liver
15. Expression and matrix deposition of latent transforming growth factor-beta binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture
16. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis
17. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis
18. The plasminogen-activating system in hepatic stellate cells
19. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration
20. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency
21. Modulation of the plasminogen activator/plasmin system in rat liver regenerating by recruitment of oval cells
22. Immediate early detection of urokinase receptor after partial hepatectomy and its implications for initiation of liver regeneration
23. Plasminogen activator inhibitor-1 is an immediate early response gene in regenerating rat liver
24. Increased expression of plasminogen activator and Plasminogen activator inhibitor during liver fibrogenesis of rats: Role of stellate cells
25. Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene
26. Gene expression and regulation of plasminogen activator inhibitor type I in hepatic stellate cells of rat liver
27. Human plasminogen activator inhibitor-1
28. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease
29. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney
30. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility
31. Structural and functional differentiation of sinusoidal endothelial cells during liver organogenesis in humans
32. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia
33. Focal nodular hyperplasia of the liver: Composition of the extracellular matrix and expression of cell-cell and cellmatrix adhesion molecules
34. Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene
35. Matricellular proteins as modulators of cell-matrix interactions: Adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2
36. Insulinlike growth factor-II/mannose 6-phosphate receptor is expressed on CC14-exposed rat fatstoring cells and facilitates activation of latent transforming growth factor-beta in cocultures with sinusoidal endothelial cells
37. Alternative mechanisms for trafficking of lysosomal enzymes in mannose 6-phosphate receptor-deficient mice are cell typespecific
38. The integrin alpha v beta 6 binds and activates latent TGF beta 1: A mechanism for regulating pulmonary inflammation and fibrosis
39. Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues
40. SPARC regulates the expression of collagen type I and transforming growth factor-betal in mesangial cells
41. Osteonectin (SPARC) expression in human liver and in cultured human liver myofibroblasts
42. TGF-beta signal transduction
43. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells
44. Defective angiogenesis in mice lacking endoglin
45. Cloning of the promoter region of human endoglin, the target gene for hereditary, hemorrhagic telangiectasia type 1
46. Hepatic involvement in hereditary hemorrhagic telangiectasia: Clinical, radiological, and hemodynamic studies of 11 cases
47. Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation
48. Vascular adhesion molecule expression in viral chronic hepatitis: Evidence of neoangiogenesis in portal tracts
49. Differential expression of transforming growth factor-beta and its receptors in hepatocytes and nonparenchymal cells of rat liver after CC14 administration
50. Role of transforming growth factor beta type II receptor in hepatic fibrosis: Studies of human chronic hepatitis C and experimental fibrosis in rats
51. Mechanisms of transforming growth factor-receptor endocytosis and intracellular sorting differ between fibroblasts and epithelial cells
52. Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor
53. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene
54. Crystal structure of a Smad MH1 domain bound to DNA Insights on DNA binding in TGF-beta signaling
55. Loss of Smad3 modulates wound healing
56. Functions of mammalian Smad genes as revealed by targeted gene disruption in mice
57. FK506 enhances fibrogenesis in in vitro and in vivo models of liver fibrosis in rats
58. The nuclear import function of Smad2 is masked by SARA and unmasked by TGFbeta-dependent phosphorylation
59. Regulation of Smad7 promoter by direct association with Smad3 and Smad4
60. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation
61. Smurfl interacts with transforming growth factor- type i receptor through Smad7 and induces receptor degradation
62. Hepatocyte growth factor gene therapy of liver cirrhosis in rats
63. Role of transforming growth factor-β signaling in cancer
64. Gamma-interferon treatment inhibits collagen deposition in murine schistosomiasis
65. Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma
66. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA
67. Structural and functional characterization of the transforming growth factor-induced Smad3/c-Jun transcriptional cooperativity
68. Long- and short-term D-alpha-tocopherol supplementation inhibits liver collagen alphal(I) gene expression
69. The hepatitis B virus encoded oncoprotein pX amplifies TGF-? Family signaling through direct interaction with Smad4: Potential mechanism of hepatitis B virus-induced liver fibrosis
70. Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor beta-related signaling
71. A novel Smad nuclear interacting protein, SNIP1, suppresses p300-dependent TGF-beta signal transduction
72. c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads
73. The Ski oncoprotein interacts with the Smad proteins to repress TGF-beta signaling
74. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein
75. Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor
76. Activin induces cell death in hepatocytes in vivo and in vitro
77. The role of activin and transforming growth factor-beta in the regulation of organ mass in the rat liver
78. Localization and cellular sources of activins in normal and fibrotic rat liver
79. Bone morphogenetic protein-6 is expressed in nonparenchymal liver cells and upregulated by transforming growth factor-beta 1
80. Bone morphogenetic protein-9. An autocrine/paracrine cytokine in the liver
81. Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat
82. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions
83. TGF-beta1 in liver fibrosis: An inducible transgenic mouse model to study liver fibrogenesis
84. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1
85. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer
86. Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma
87. Specific binding of endocrine transforming growth factor-beta 1 to vascular endothelium
88. Alpha2-macroglobulin reduces paracrineand autocrine-stimulated matrix synthesis of cultured rat hepatic stellate cells
89. Characterization and regulation of the latent transforming growth factor-beta complex secreted by vascular pericytes
90. Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion
91. Immunological measurement of transforming growth factor-beta 1
92. Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma
93. Role of elevated plasma transforming growth factorbetal levels in wound healing
94. Innate and adaptive lymphoid cells in the human liver
95. Regulation of immune responses by TGF-beta
96. Host genetic factors influence disease progression in chronic hepatitis C
97. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C
98. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat
99. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats
100. Characterization of recombinant soluble human transforming growth factor-beta receptor type II (rhTGF-beta sRII)
101. Transforming growth factor-beta initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform
102. Expression of variant fibronectins in wound healing: Cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis
103. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters
104. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth
105. The recombinant proregion of transforming growth factor betal
106. Early alcoholic liver injury. Activation of lipocytes in acinar zone 3 and correlation to degree of collagen formation in the Disse space
107. In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation
108. PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury
109. Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells
110. Transforming growth factor-beta promotes epidermal growth factor-induced thyroid cell migration and follicle neoformation in collagen gel separable from cell proliferation
111. Differential modulation of hepatocyte growth factor-stimulated motility by transforming growth factor beta1 on rat liver epithelial cells in vitro
112. Transforming growth factor beta
113. Hepatocyte growth factor releases mink epithelial cells from transforming growth factor betal-induced growth arrest by restoring Cdk6 expression and cyclin E-associated Cdk2 activity
114. Induction of platelet-derived growth factor B-chain expression by transforming growth factor-beta involves transactivation by Smads
115. Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts
116. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: A potential new therapy for hepatic fibrosis
117. The role of TGFbetal in initiating hepatic stellate cell activation in vivo
118. Levels of transforming growth factor beta and transforming growth factor beta receptors in rat liver during growth, regression by apoptosis and neoplasia
119. Activation of caspase-8 in transforming growth factorbeta-induced apoptosis of human hepatoma cells
120. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways
121. Molecular cloning and characterization of TIEG2 reveals a new subfamily of transforming growth factor-beta-inducible Spl-like zinc finger-encoding genes involved in the regulation of cell growth
122. The transforming growth factor beta1-inducible transcription factor, TIEG1, mediates apoptosis through oxidative stress
123. The herbal medicine Inchin-ko-to inhibits liver cell apoptosis induced by transforming growth factor beta 1
124. Dysregulation of apoptosis in hepatocellular carcinoma
125. Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta
126. Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma
127. Smad3 mutant mice develop metastatic colorectal cancer
128. Analysis of transforming growth factor
129. Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma
130. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers
131. Gene mutation of transforming growth factor betal type II receptor in hepatocellular carcinoma
132. Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma
133. Mutation analysis of the transforming growth factor beta type II receptor in sporadic human cancers of the pancreas, liver, and breast
134. Smad2 and Smad4 gene mutations in hepatocellular carcinoma
135. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis
136. Failure to detect genetic alteration of the mannose-6-phosphate/insulin-like growth factor 2 receptor
137. Regulatory mechanisms for transforming growth factor beta as an autocrine inhibitor in human hepatocellular carcioma: Implications for roles of Smads in its growth